Emalex Biosciences Email Format

Biotechnology ResearchIllinois, United States51-200 Employees

Emalex Biosciences is a Chicago-based biotechnology company focused on developing therapies for central nervous system disorders, with a late-stage program aimed at Tourette syndrome and other neurological conditions. The company was founded in 2018 when Paragon Biosciences established it to pursue novel CNS treatments, and it operates with a mid-sized team in the biotechnology research sector. Its activities center on advancing drug candidates through late-stage development to address unmet needs in neurology.

Its lead asset, ecopipam, targets the D1 receptor pathway associated with tic expression and is being developed for Tourette syndrome. In 2026, Teva Pharmaceutical Industries completed the acquisition of Emalex Biosciences, a move described as strengthening Teva's late-stage pipeline with ecopipam.

Sign up for free to view info

Company overview Employee directory